{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:29:53Z","timestamp":1794274193804,"version":"4.9.0"},"reference-count":49,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,4,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>With defined chemotherapy and radiotherapy (RT) and risk-adapted treatment, early-stage classical Hodgkin lymphoma (HL) has become curable in a majority of patients. Hence, a major current goal is to reduce treatment-related toxicity while maintaining long-term disease control. Patients with early-stage favorable disease (ie, limited stage without risk factors [RFs]) are frequently treated with 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (2\u00d7ABVD) followed by 20-Gy involved-field or involved-site RT (IF\/ISRT). In patients with early-stage unfavorable disease (ie, limited stage with RFs), 4 cycles of chemotherapy are usually consolidated with 30-Gy IF\/ISRT. Compared with 4\u00d7ABVD, 2 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (2\u00d7BEACOPPescalated) followed by 2\u00d7ABVD improved 5-year progression-free survival (PFS), with similar 5-year overall survival. Recently, treatment strategies based on [18F]fluorodeoxyglucose positron emission tomography (PET) response were evaluated. In early-stage unfavorable HL, a majority of patients achieved a negative interim PET after 2\u00d7ABVD and an excellent outcome after 4\u00d7ABVD, whereas in those with a positive interim PET, 2\u00d7BEACOPPescalated improved 5-year PFS. Furthermore, a PET-guided RT approach was evaluated to decrease long-term toxicity. Although both the RAPID and H10 trials reported poorer disease control without RT, PET-guided omission of RT can constitute a valid therapeutic option in patients with an increased risk of RT-associated toxicity (eg, because of sex, age, or disease localization). Implementation of drugs such as the anti-CD30 antibody-drug conjugate brentuximab vedotin or the anti\u2013programmed death 1 antibodies nivolumab or pembrolizumab might allow further reduction of overall mortality and improve quality of life in affected patients.<\/jats:p>","DOI":"10.1182\/blood-2017-10-772665","type":"journal-article","created":{"date-parts":[[2018,3,2]],"date-time":"2018-03-02T18:15:23Z","timestamp":1520014523000},"page":"1666-1678","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":40,"title":["Balancing risk and benefit in early-stage classical Hodgkin lymphoma"],"prefix":"10.1182","volume":"131","author":[{"given":"Paul J.","family":"Br\u00f6ckelmann","sequence":"first","affiliation":[{"name":"Department I of Internal Medicine and German Hodgkin Study Group (GHSG), University Hospital of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Sasse","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine and German Hodgkin Study Group (GHSG), University Hospital of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Engert","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine and German Hodgkin Study Group (GHSG), University Hospital of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"9976","key":"2019111908015800700_B1","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/S0140-6736(14)61469-0","article-title":"Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin\u2019s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial","volume":"385","author":"Behringer","year":"2015","journal-title":"Lancet"},{"issue":"9","key":"2019111908015800700_B2","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1200\/JCO.2011.38.5807","article-title":"Dose-intensification in early unfavorable Hodgkin\u2019s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial","volume":"30","author":"von Tresckow","year":"2012","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111908015800700_B3","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1093\/annonc\/mdt413","article-title":"Impact of risk factors on outcomes in early-stage Hodgkin\u2019s lymphoma: an analysis of international staging definitions","volume":"24","author":"Klimm","year":"2013","journal-title":"Ann Oncol"},{"issue":"26","key":"2019111908015800700_B4","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40 years after treatment for Hodgkin\u2019s lymphoma","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N Engl J Med"},{"issue":"18","key":"2019111908015800700_B5","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.2016.70.9410","article-title":"Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: updated analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 trials","volume":"35","author":"Sasse","year":"2017","journal-title":"J Clin Oncol"},{"issue":"16","key":"2019111908015800700_B6","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111908015800700_B7","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/bjh.13646","article-title":"Impact of centralized diagnostic review on quality of initial staging in Hodgkin lymphoma: experience of the German Hodgkin Study Group","volume":"171","author":"Br\u00f6ckelmann","year":"2015","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111908015800700_B8","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1093\/annonc\/mdq428","article-title":"Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma","volume":"22","author":"Barrington","year":"2011","journal-title":"Ann Oncol"},{"issue":"2","key":"2019111908015800700_B9","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s11307-009-0259-3","article-title":"On the added value of baseline FDG-PET in malignant lymphoma","volume":"12","author":"Quarles van Ufford","year":"2010","journal-title":"Mol Imaging Biol"},{"issue":"36","key":"2019111908015800700_B10","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1200\/JCO.2012.42.4036","article-title":"Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography\/computed tomography-staged treatment-naive patients with Hodgkin lymphoma","volume":"30","author":"El-Galaly","year":"2012","journal-title":"J Clin Oncol"},{"issue":"27","key":"2019111908015800700_B11","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111908015800700_B12","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/annonc\/mdx097","article-title":"International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)","volume":"28","author":"Younes","year":"2017","journal-title":"Ann Oncol"},{"issue":"5","key":"2019111908015800700_B13","doi-asserted-by":"crossref","first-page":"608","DOI":"10.6004\/jnccn.2017.0064","article-title":"Hodgkin lymphoma version 1.2017, NCCN clinical practice guidelines in oncology","volume":"15","author":"Hoppe","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"key":"2019111908015800700_B14","article-title":"Hodgkin lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","author":"Eichenauer","journal-title":"Ann Oncol"},{"issue":"23","key":"2019111908015800700_B15","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1200\/JCO.2006.07.0482","article-title":"Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin\u2019s lymphoma: final results of the GHSG HD7 trial","volume":"25","author":"Engert","year":"2007","journal-title":"J Clin Oncol"},{"issue":"19","key":"2019111908015800700_B16","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1056\/NEJMoa064601","article-title":"Chemotherapy plus involved-field radiation in early-stage Hodgkin\u2019s disease","volume":"357","author":"Ferm\u00e9","year":"2007","journal-title":"N Engl J Med"},{"issue":"19","key":"2019111908015800700_B17","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1200\/JCO.2005.05.2746","article-title":"Combined-modality therapy for clinical stage I or II Hodgkin\u2019s lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials","volume":"24","author":"Noordijk","year":"2006","journal-title":"J Clin Oncol"},{"issue":"14","key":"2019111908015800700_B18","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.2004.12.170","article-title":"ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin\u2019s disease: long-term results","volume":"22","author":"Bonadonna","year":"2004","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111908015800700_B19","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"2019111908015800700_B20","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.radonc.2006.05.015","article-title":"Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines","volume":"79","author":"Girinsky","year":"2006","journal-title":"Radiother Oncol"},{"issue":"7","key":"2019111908015800700_B21","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.clon.2015.03.005","article-title":"Involved node, site, field and residual volume radiotherapy for lymphoma: a comparison of organ at risk dosimetry and second malignancy risks","volume":"27","author":"Murray","year":"2015","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"12","key":"2019111908015800700_B22","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1093\/annonc\/mdt389","article-title":"An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma","volume":"24","author":"Hay","year":"2013","journal-title":"Ann Oncol"},{"issue":"6","key":"2019111908015800700_B23","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1200\/JCO.2014.58.7543","article-title":"Treatment selection and outcomes in early-stage classical Hodgkin lymphoma: analysis of the National Cancer Data Base","volume":"33","author":"Olszewski","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111908015800700_B24","first-page":"CD007110","article-title":"Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma","author":"Blank","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"2019111908015800700_B25","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111908015800700_B26","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2013.51.9298","article-title":"Omitting radiotherapy in early positron emission tomography-negative stage I\/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"32","author":"Raemaekers","year":"2014","journal-title":"J Clin Oncol"},{"issue":"17","key":"2019111908015800700_B27","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"issue":"23","key":"2019111908015800700_B28","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.578.578","article-title":"Initial results of US Intergroup trial of response-adapted chemotherapy or chemotherapy\/radiation therapy based on PET for non-bulky stage I and II Hodgkin lymphoma (HL) (CALGB\/Alliance 50604) [abstract]","volume":"126","author":"Straus","year":"2015","journal-title":"Blood"},{"issue":"9","key":"2019111908015800700_B29","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/S1470-2045(16)30215-7","article-title":"Cumulative burden of cardiovascular morbidity in paediatric, adolescent, and young adult survivors of Hodgkin\u2019s lymphoma: an analysis from the St Jude Lifetime Cohort Study","volume":"17","author":"Bhakta","year":"2016","journal-title":"Lancet Oncol"},{"issue":"18","key":"2019111908015800700_B30","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1182\/blood-2015-11-681064","article-title":"Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials","volume":"127","author":"B\u00f6ll","year":"2016","journal-title":"Blood"},{"issue":"13","key":"2019111908015800700_B31","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1200\/JCO.2016.71.3289","article-title":"Late relapse of classical Hodgkin lymphoma: an analysis of the German Hodgkin Study Group HD7 to HD12 trials","volume":"35","author":"Br\u00f6ckelmann","year":"2017","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111908015800700_B32","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1111961","article-title":"ABVD alone versus radiation-based therapy in limited-stage Hodgkin\u2019s lymphoma","volume":"366","author":"Meyer","year":"2012","journal-title":"N Engl J Med"},{"issue":"19","key":"2019111908015800700_B33","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1200\/JCO.2003.03.023","article-title":"Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin\u2019s lymphoma: results of the HD8 trial of the German Hodgkin\u2019s Lymphoma Study Group","volume":"21","author":"Engert","year":"2003","journal-title":"J Clin Oncol"},{"issue":"27","key":"2019111908015800700_B34","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2010.29.8018","article-title":"Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin\u2019s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial","volume":"28","author":"Eich","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111908015800700_B35","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0360-3016(97)00085-0","article-title":"Stage IA-IIB Hodgkin\u2019s disease: management and outcome of extensive thoracic involvement","volume":"39","author":"Hughes-Davies","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"13","key":"2019111908015800700_B36","article-title":"Impact of dose intensification on the outcome in early-stage unfavorable HL: 7-year follow-up analysis of the GHSG HD14 trial [abstract]","volume":"98","author":"Sasse","year":"2013","journal-title":"Haematologica"},{"issue":"17","key":"2019111908015800700_B37","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1200\/JCO.2014.57.8138","article-title":"Randomized phase III trial comparing ABVD plus radiotherapy with the Stanford V regimen in patients with stages I or II locally extensive, bulky mediastinal Hodgkin lymphoma: a subset analysis of the North American Intergroup E2496 trial","volume":"33","author":"Advani","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111908015800700_B38","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1182\/blood-2011-09-378414","article-title":"A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era","volume":"119","author":"Evens","year":"2012","journal-title":"Blood"},{"issue":"22","key":"2019111908015800700_B39","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1200\/JCO.2005.11.080","article-title":"Hodgkin\u2019s lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin\u2019s Study Group","volume":"23","author":"Engert","year":"2005","journal-title":"J Clin Oncol"},{"issue":"22","key":"2019111908015800700_B40","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1200\/JCO.2012.47.9774","article-title":"Treatment-related mortality in patients with advanced-stage hodgkin lymphoma: an analysis of the German Hodgkin Study Group","volume":"31","author":"Wongso","year":"2013","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111908015800700_B41","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1200\/JCO.2012.45.4181","article-title":"ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials","volume":"31","author":"B\u00f6ll","year":"2013","journal-title":"J Clin Oncol"},{"issue":"18","key":"2019111908015800700_B42","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111908015800700_B43","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"issue":"19","key":"2019111908015800700_B44","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111908015800700_B45","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3324\/haematol.2016.150656","article-title":"The emerging role of immune checkpoint inhibition in malignant lymphoma","volume":"102","author":"Hude","year":"2017","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2019111908015800700_B46","article-title":"A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma [abstract]","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2019111908015800700_B47","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1182\/blood-2017-04-773838","article-title":"Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation","volume":"131","author":"Akhtari","year":"2018","journal-title":"Blood"},{"issue":"22","key":"2019111908015800700_B48","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1182\/blood-2017-03-770719","article-title":"Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma","volume":"130","author":"Carey","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2019111908015800700_B49","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/S2352-3026(14)00039-8","article-title":"Non-invasive detection of genomic imbalances in Hodgkin\/Reed-Sternberg cells in early and advanced stage Hodgkin\u2019s lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study","volume":"2","author":"Vandenberghe","year":"2015","journal-title":"Lancet Haematol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/131\/15\/1666\/1405685\/blood772665.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/131\/15\/1666\/1405685\/blood772665.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T13:02:51Z","timestamp":1574168571000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/131\/15\/1666\/36825\/Balancing-risk-and-benefit-in-earlystage-classical"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,12]]},"references-count":49,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2018,4,12]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2017-10-772665","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,12]]}}}